JAAHA Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tumulty, J. W.
Right arrow Articles by Williams, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tumulty, J. W.
Right arrow Articles by Williams, D. A.
Journal of the American Animal Hospital Association 40:120-123 (2004)
© 2004 American Animal Hospital Association

Original Article

Clinical Effects of Short-Term Oral Budesonide on the Hypothalamic-Pituitary-Adrenal Axis in Dogs With Inflammatory Bowel Disease

Joshua W. Tumulty, DVM, Diplomate ACVIM, John D. Broussard, DVM, Diplomate ACVIM, Jörg M. Steiner, med.vet., Dr.med.vet., PhD, Diplomate ACVIM, Diplomate ECVIM-CA, Mark E. Peterson, DVM, Diplomate ACVIM and David A. Williams, MA, Vet. MB, PhD, MRCVS, Diplomate ACVIM

From the The Animal Medical Center (Tumulty, Broussard, Peterson), E & M Bobst Hospital, Caspary Research Institute, 510 East 62nd Street, New York, New York 10021-8314 and the Gastrointestinal Laboratory (Steiner, Williams), Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, Texas A&M University, College Station, Texas 77843-4474.

Six dogs were entered into a 30-day, prospective, nonrandomized, uncontrolled clinical trial evaluating the effects of an oral preparation of budesonide on the hypothalamic-pituitary-adrenal (HPA) axis during therapeutic management of active inflammatory bowel disease. Oral budesonide, at a dose of 3 mg/m2, was administered once daily. Upon entry and completion of the trial, serum basal cortisol, adrenocorticotropic (ACTH)-stimulated cortisol, endogenous ACTH concentration, serum alkaline phosphatase (SAP) activity, and urine specific gravity were evaluated, as well as owner assessment of glucocorticoid-associated side effects. Significant suppression of the HPA axis occurred. No significant differences in SAP activity, urine specific gravity, or owner-subjective assessments were detected.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Animal Hospital Association.